153 results

Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 2/3 105 participants Johns Hopkins University

Alcohol Use Disorder (AUD), Withdrawal From Addictive Substance; Detoxification, Craving

Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 2/3 60 participants The Royal's Institute of Mental Health Research

Treatment Resistant Depression, Major Depressive Disorder (MDD)

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 2/3 300 participants COMPASS Pathways

PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 240 participants VA Office of Research and Development

Major Depression

Online Mindfulness-Based Cognitive Therapy for People With Multiple Sclerosis With Mild-Moderate Depression (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 152 participants Robert Simpson

Multiple Sclerosis

Tirzepatide in the Treatment of Cannabis Use Disorder (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 15 participants McMaster University

Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe

A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 348 participants Janssen Research & Development, LLC

Depressive Disorder, Treatment-Resistant

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 172 participants Centre Hospitalier Universitaire de Nīmes

Alcohol Use Disorder, Depressive Sympotoms, Psilocybin

MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 2/3 80 participants VA Office of Research and Development

Post Traumatic Stress Disorder, Alcohol Use Disorder

InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 31 participants Sunnybrook Health Sciences Centre

Treatment Resistant Depression

Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 90 participants Lakshmi N Yatham

Bipolar II Depression

Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 60 participants Khyber Medical University Peshawar

Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD)

Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 160 participants University of Cincinnati

Mild Depression

Sustained Mood Improvement With Laughing Gas Exposure (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 120 participants Women's College Hospital

Major Depressive Disorder, Treatment Resistant Depression

Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT) (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 120 participants Bruyère Health Research Institute.

Psychological Distress

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 258 participants Janssen Research & Development, LLC

Depressive Disorder, Major

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 330 participants Cybin IRL Limited

Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders

The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series (opens ClinicalTrials.gov in a new tab)

Withdrawn Phase 2/3 0 participants Washington University School of Medicine

Postpartum Depression

Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 34 participants University of Utah

Breast Cancer, Gynecologic Cancer

Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 220 participants Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Depressive Disorder

Combination Gerotherapeutic Interventions for Healthspan Improvement (opens ClinicalTrials.gov in a new tab)

Active, not recruiting Phase 3 30 participants AgelessRx

Healthspan Improvement, Aging, Longevity

Ketamine Augmentation of ECT in Treatment-Resistant Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 30 participants Università Vita-Salute San Raffaele

Major Depressive Disorder, Treatment Resistant Depression

E-Mindfulness Approaches for Living After Breast Cancer (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 402 participants NRG Oncology

Breast Cancer, Depression

Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 3 60 participants Federal University of São Paulo

Depressive Disorder, Suicidal Ideas

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 3 1,254 participants Dr. Inge Winter

Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression